Aurintricarboxylic acid is a canonical disruptor of the TAZ-TEAD transcriptional complex

被引:5
|
作者
Che, Kepeng [1 ]
Pobbati, Ajaybabu, V [1 ]
Seavey, Caleb N. [1 ,2 ]
Fedorov, Yuriy [3 ]
Komar, Anton A. [4 ,5 ]
Burtscher, Ashley [1 ]
Ma, Shuang [1 ]
Rubin, Brian P. [1 ,6 ]
机构
[1] Cleveland Clin, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44106 USA
[2] Cleveland Clin, Digest Dis & Surg Inst, Dept Gen Surg, Cleveland, OH 44106 USA
[3] Case Western Reserve Univ, Sch Med, Small Mol Drug Dev Core, Cleveland, OH USA
[4] Cleveland State Univ, Ctr Gene Regulat Hlth & Dis, Dept Biol Geol & Environm Sci, Cleveland, OH 44115 USA
[5] Cleveland Clin, Lerner Res Inst, Genom Med Inst, Cleveland, OH 44106 USA
[6] Cleveland Clin, Robert J Tomsich Pathol & Lab Med Inst, Cleveland, OH 44106 USA
来源
PLOS ONE | 2022年 / 17卷 / 04期
关键词
HIPPO PATHWAY; YAP; YAP/TAZ; COACTIVATORS; PEPTIDES; FUSION;
D O I
10.1371/journal.pone.0266143
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Disrupting the formation of the oncogenic YAP/TAZ-TEAD transcriptional complex holds substantial therapeutic potential. However, the three protein interaction interfaces of this complex cannot be easily disrupted using small molecules. Here, we report that the pharmacologically active small molecule aurintricarboxylic acid (ATA) acts as a disruptor of the TAZ-TEAD complex. ATA was identified in a high-throughput screen using a TAZ-TEAD AlphaLISA assay that was tailored to identify disruptors of this transcriptional complex. We further used fluorescence polarization assays both to confirm disruption of the TAZ-TEAD complex and to demonstrate that ATA binds to interface 3. We have previously shown that cell-based models that express the oncogenic TAZ-CAMTA1 (TC) fusion protein display enhanced TEAD transcriptional activity because TC functions as an activated form of TAZ. Utilizing cell-based studies and our TC model system, we performed TC/TEAD reporter, RNA-Seq, and qPCR assays and found that ATA inhibits TC/TEAD transcriptional activity. Further, disruption of TC/TEAD and TAZ/TEAD interaction by ATA abrogated anchorage-independent growth, the phenotype most closely linked to dysregulated TAZ/TEAD activity. Therefore, this study demonstrates that ATA is a novel small molecule that has the ability to disrupt the undruggable TAZ-TEAD interface.
引用
收藏
页数:16
相关论文
共 50 条
  • [41] TARGETING OF THE YAP/TAZ-TEAD AXIS DIMINISHES VIABILITY AND DIFFERENTIATION POTENTIAL IN PEDIATRIC HIGH-GRADE GLIOMA
    Macias, Jorge Luis Jimenez
    Oh, Se-Yeong
    Hu, Zhengang
    Yin, Kevin
    Sele, Nisan
    Boon, Nikki
    Sing, Anson
    Sloan, Steven A.
    Read, Renee D.
    NEURO-ONCOLOGY, 2024, 26
  • [42] The Hippo Pathway and YAP/TAZ-TEAD Protein-Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment
    Santucci, Matteo
    Vignudelli, Tatiana
    Ferrari, Stefania
    Mor, Marco
    Scalvini, Laura
    Bolognesi, Maria Laura
    Uliassi, Elisa
    Costi, Maria Paola
    JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (12) : 4857 - 4873
  • [43] Structural dynamics-based hit generation to disrupt YAP/TAZ-TEAD protein-protein interaction.
    Du, Lin
    Liu, Jing
    Zeng, Qinglong
    Xu, Ming
    Lu, Jiting
    Zheng, Qiangang
    Zhu, Jidong
    CANCER RESEARCH, 2021, 81 (13)
  • [44] Targeting YAP/TAZ-TEAD protein-protein interactions using fragment-based and computational modeling approaches
    Kaan, Hung Yi Kristal
    Sim, Adelene Y. L.
    Tan, Siew Kim Joyce
    Verma, Chandra
    Song, Haiwei
    PLOS ONE, 2017, 12 (06):
  • [45] Discovery of novel potent allosteric inhibitors of YAP/TAZ-TEAD transcription for the treatment of multiple solid tumor types addicted to Hippo signaling
    Versele, Matthias
    Candi, Aurelie
    Nijs, Marnik
    Haeck, Wanda
    Klaassen, Hugo
    Smets, Wim
    Spieser, Stephane
    Vanderhoydonck, Bart
    Marchand, Arnaud
    Chaltin, Patrick
    Sansores, Leticia
    Halder, Georg
    CANCER RESEARCH, 2020, 80 (16)
  • [46] The novel potent Pan-TEAD inhibitor, SB6863, inhibits oncogenic YAP1/TAZ-TEAD signaling and exhibits robust tumor regression in preclinical mesothelioma models
    Lee, O. Y.
    Jeong, Y.
    Park, Y.
    Kim, J. G.
    Choi, S.
    Jung, H. S.
    Kong, Y.
    Baek, G. R.
    Kim, J. H.
    Kim, H. E.
    Yoo, J. W.
    Park, J. H.
    Jeong, H. U.
    Park, H.
    Kim, M. K.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S52 - S52
  • [47] YAP/TAZ-TEAD activity promotes the malignant transformation of cervical intraepithelial neoplasia through enhancing the characteristics and Warburg effect of cancer stem cells
    Li, Shu
    Li, Xing
    Yang, Yong-bin
    Wu, Su-fang
    APOPTOSIS, 2024, 29 (7-8) : 1198 - 1210
  • [48] Establishment of transgenic lines to monitor and manipulate Yap/Taz-Tead activity in zebrafish reveals both evolutionarily conserved and divergent functions of the Hippo pathway
    Miesfeld, Joel B.
    Link, Brian A.
    MECHANISMS OF DEVELOPMENT, 2014, 133 : 177 - 188
  • [49] Discovery of a first-in-class TEAD inhibitor which directly inhibits YAP/TAZ-TEAD protein-protein interaction and shows a potent anti-tumor effect in malignant pleural mesothelioma
    Kaneda, Ayumi
    Seike, Toshihiro
    Uemori, Takeshi
    Myojo, Kensuke
    Aida, Kensuke
    Danjo, Tomohiro
    Nakajima, Takahiro
    Yamaguchi, Daisuke
    Hamada, Tomoko
    Tsuji, Yoshiro
    Hamaguchi, Kaori
    Yasunaga, Mai
    Otsubo, Nobumasa
    Onodera, Hideyuki
    Nishiya, Yoichi
    Suzuki, Michihiko
    Saito, Junichi
    Ishii, Toshihiko
    Nakai, Ryuichiro
    CANCER RESEARCH, 2019, 79 (13)
  • [50] The novel potent TEAD inhibitor, K-975, inhibits YAP1/TAZ-TEAD protein-protein interactions and exerts an anti-tumor effect on malignant pleural mesothelioma
    Kaneda, Ayumi
    Seike, Toshihiro
    Danjo, Tomohiro
    Nakajima, Takahiro
    Otsubo, Nobumasa
    Yamaguchi, Daisuke
    Tsuji, Yoshiro
    Hamaguchi, Kaori
    Yasunaga, Mai
    Nishiya, Yoichi
    Suzuki, Michihiko
    Saito, Jun-ichi
    Yatsunami, Rie
    Nakamura, Satoshi
    Sekido, Yoshitaka
    Mori, Kiyotoshi
    AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 10 (12): : 4399 - 4415